FindTrial
Sign In

KRN23

DRUG11 trials

Sponsors

Kyowa Kirin Co., Ltd., Kyowa Kirin, Inc.

Conditions

Tumor-Induced Osteomalacia (TIO)Tumor-Induced Osteomalacia or Epidermal Nevus SyndromeX-Linked HypophosphatemiaX-linked HypophosphatemiaX-linked Hypophosphatemia (XLH)X-linked Hypophosphatemic Rickets/OsteomalaciaXLH

Phase 1

A Study of KRN23 in X-linked Hypophosphatemia
CompletedNCT00830674
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemia
Start: 2008-12-31End: 2013-05-31Updated: 2024-06-17
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
CompletedNCT01340482
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemia
Start: 2011-04-30End: 2013-10-31Updated: 2024-06-18
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
CompletedNCT01571596
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemia
Start: 2012-02-29End: 2014-06-30Updated: 2024-06-18
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
CompletedNCT02181764
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemic Rickets/Osteomalacia
Start: 2014-07-31End: 2015-06-30Updated: 2017-03-03

Phase 2

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
CompletedNCT02312687
Kyowa Kirin, Inc.X-Linked Hypophosphatemia
Start: 2015-01-30End: 2018-11-30Updated: 2024-05-06
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
CompletedNCT02722798
Kyowa Kirin Co., Ltd.Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Start: 2016-04-30End: 2020-10-31Updated: 2022-09-06

Phase 3

A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
CompletedNCT03233126
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemic Rickets/Osteomalacia
Start: 2017-07-06End: 2020-02-17Updated: 2022-09-06
A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
CompletedNCT04308096
Kyowa Kirin Co., Ltd.XLH
Start: 2018-01-09End: 2020-12-04Updated: 2022-09-06

Phase 4

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
CompletedNCT04842019
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemia (XLH)
Start: 2021-09-28End: 2023-08-17Updated: 2024-07-09
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
CompletedNCT04842032
Kyowa Kirin Co., Ltd.X-linked Hypophosphatemia (XLH)
Start: 2021-11-01End: 2023-12-18Updated: 2024-07-09
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO
CompletedNCT05357573
Kyowa Kirin Co., Ltd.Tumor-Induced Osteomalacia (TIO)
Start: 2022-09-07End: 2023-12-22Updated: 2024-07-09

Related Papers

Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study
Journal of Bone and Mineral Research2024-08-1615 citations
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
RMD Open2023-02-0133 citations
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
2023-01-316 citations
Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism2022-09-0828 citations
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Journal of Clinical Investigation2014-02-24313 citations